JP2014518377A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518377A5 JP2014518377A5 JP2014513712A JP2014513712A JP2014518377A5 JP 2014518377 A5 JP2014518377 A5 JP 2014518377A5 JP 2014513712 A JP2014513712 A JP 2014513712A JP 2014513712 A JP2014513712 A JP 2014513712A JP 2014518377 A5 JP2014518377 A5 JP 2014518377A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- jcv
- determined
- vla
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 131
- 241000701460 JC polyomavirus Species 0.000 claims description 71
- 238000002560 therapeutic procedure Methods 0.000 claims description 71
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 70
- 230000005764 inhibitory process Effects 0.000 claims description 63
- 239000000523 sample Substances 0.000 claims description 59
- 239000012472 biological sample Substances 0.000 claims description 31
- 238000011866 long-term treatment Methods 0.000 claims description 25
- 239000011541 reaction mixture Substances 0.000 claims description 24
- 230000027455 binding Effects 0.000 claims description 22
- 239000003018 immunosuppressive agent Substances 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 16
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 10
- 229960005027 natalizumab Drugs 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 229960003776 glatiramer acetate Drugs 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 238000012790 confirmation Methods 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 230000001861 immunosuppressant effect Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000013641 positive control Substances 0.000 claims description 3
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 238000009175 antibody therapy Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161491810P | 2011-05-31 | 2011-05-31 | |
| US61/491,810 | 2011-05-31 | ||
| US201161508584P | 2011-07-15 | 2011-07-15 | |
| US61/508,584 | 2011-07-15 | ||
| US201161550257P | 2011-10-21 | 2011-10-21 | |
| US61/550,257 | 2011-10-21 | ||
| US201261636588P | 2012-04-20 | 2012-04-20 | |
| US61/636,588 | 2012-04-20 | ||
| PCT/US2012/040283 WO2012166971A2 (en) | 2011-05-31 | 2012-05-31 | Method of assessing risk of pml |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017144730A Division JP6663396B2 (ja) | 2011-05-31 | 2017-07-26 | Ｐｍｌの危険性を査定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518377A JP2014518377A (ja) | 2014-07-28 |
| JP2014518377A5 true JP2014518377A5 (enExample) | 2015-07-23 |
| JP6243838B2 JP6243838B2 (ja) | 2017-12-06 |
Family
ID=47260338
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513712A Active JP6243838B2 (ja) | 2011-05-31 | 2012-05-31 | Ｐｍｌの危険性を査定する方法 |
| JP2017144730A Active JP6663396B2 (ja) | 2011-05-31 | 2017-07-26 | Ｐｍｌの危険性を査定する方法 |
| JP2020023062A Active JP7128221B2 (ja) | 2011-05-31 | 2020-02-14 | Ｐｍｌの危険性を査定する方法 |
| JP2021168084A Active JP7353338B2 (ja) | 2011-05-31 | 2021-10-13 | Ｐｍｌの危険性を査定する方法 |
| JP2023151467A Pending JP2023169307A (ja) | 2011-05-31 | 2023-09-19 | Ｐｍｌの危険性を査定する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017144730A Active JP6663396B2 (ja) | 2011-05-31 | 2017-07-26 | Ｐｍｌの危険性を査定する方法 |
| JP2020023062A Active JP7128221B2 (ja) | 2011-05-31 | 2020-02-14 | Ｐｍｌの危険性を査定する方法 |
| JP2021168084A Active JP7353338B2 (ja) | 2011-05-31 | 2021-10-13 | Ｐｍｌの危険性を査定する方法 |
| JP2023151467A Pending JP2023169307A (ja) | 2011-05-31 | 2023-09-19 | Ｐｍｌの危険性を査定する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US12105090B2 (enExample) |
| EP (3) | EP2715352B1 (enExample) |
| JP (5) | JP6243838B2 (enExample) |
| KR (3) | KR102473834B1 (enExample) |
| CN (1) | CN103635803A (enExample) |
| AU (1) | AU2012262122B2 (enExample) |
| CA (1) | CA2836490A1 (enExample) |
| CY (1) | CY1121981T1 (enExample) |
| DK (2) | DK2715352T3 (enExample) |
| ES (2) | ES2729945T3 (enExample) |
| FI (1) | FI3575792T3 (enExample) |
| HR (2) | HRP20230186T1 (enExample) |
| HU (2) | HUE061244T2 (enExample) |
| LT (2) | LT2715352T (enExample) |
| PL (2) | PL2715352T3 (enExample) |
| PT (2) | PT2715352T (enExample) |
| RS (2) | RS58967B1 (enExample) |
| SI (2) | SI3575792T1 (enExample) |
| SM (2) | SMT201900336T1 (enExample) |
| WO (1) | WO2012166971A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007100770A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| RS20080391A (sr) | 2006-03-03 | 2009-07-15 | Elan Pharmaceuticals Inc., | Postupci lečenja zapaljenskih i autoimunih bolesti natalizumabom |
| JP2013507618A (ja) | 2009-10-11 | 2013-03-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ｖｌａ‐４関連アッセイ |
| US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
| RS63744B1 (sr) | 2010-01-11 | 2022-12-30 | Biogen Ma Inc | Test za antitela protiv jc virusa |
| ES2729945T3 (es) | 2011-05-31 | 2019-11-07 | Biogen Ma Inc | Procedimiento para valorar el riesgo de LMP |
| HK1216546A1 (zh) | 2013-05-28 | 2016-11-18 | Biogen Ma Inc. | 评估pml风险的方法 |
| US20160223565A1 (en) * | 2013-09-18 | 2016-08-04 | The Johns Hopkins University | Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk |
| WO2015131078A1 (en) | 2014-02-27 | 2015-09-03 | Biogen Ma Inc. | Method of assessing risk of pml |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| US20210188982A1 (en) | 2017-10-26 | 2021-06-24 | Biogen Ma Inc. | Extended interval dosing of natalizumab |
| JP2023549816A (ja) | 2020-11-14 | 2023-11-29 | バイオジェン・エムエイ・インコーポレイテッド | 抗ｖｌａ－４抗体の二期皮下投与レジメン |
| EP4323407A1 (en) | 2021-04-13 | 2024-02-21 | Biogen MA Inc. | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4235601A (en) | 1979-01-12 | 1980-11-25 | Thyroid Diagnostics, Inc. | Test device and method for its use |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| US4703017C1 (en) | 1984-02-14 | 2001-12-04 | Becton Dickinson Co | Solid phase assay with visual readout |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US5763262A (en) | 1986-09-18 | 1998-06-09 | Quidel Corporation | Immunodiagnostic device |
| ES2150428T3 (es) | 1987-04-27 | 2000-12-01 | Unilever Nv | Ensayos de union especifica. |
| US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| US4818677A (en) | 1987-12-03 | 1989-04-04 | Monoclonal Antibodies, Inc. | Membrane assay using focused sample application |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US5221616A (en) | 1988-07-15 | 1993-06-22 | Quidel Corporation | Prevention of spontaneous complement activation in mammalian biological fluids |
| US5118630A (en) | 1988-11-04 | 1992-06-02 | Quidel Corporation | Method for determining periodic infertility in females |
| US6352862B1 (en) | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US5084828A (en) | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
| US5252496A (en) | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
| US5096837A (en) | 1990-02-08 | 1992-03-17 | Pacific Biotech, Inc. | Immunochromatographic assay and method of using same |
| US5223220A (en) | 1990-03-27 | 1993-06-29 | Pacific Biotech, Inc. | Solid phase immunoassay device and method of making same |
| US5118428A (en) | 1990-11-13 | 1992-06-02 | Quidel | Method to remove red blood cells from whole blood samples |
| DE4139840B4 (de) | 1990-12-04 | 2005-06-02 | Quidel Corp., San Diego | Antigen-Zubereitung zum Nachweis von H. pylori |
| WO1992012428A1 (en) | 1991-01-11 | 1992-07-23 | Quidel Corporation | A one-step lateral flow nonbibulous assay |
| US5213796A (en) | 1991-05-06 | 1993-05-25 | Dana Farber Cancer Institute | Assay for polyomavirus in humans and uses thereof |
| US5225328A (en) | 1991-05-30 | 1993-07-06 | Quidel Corporation | Stable alkaline phosphatase compositions with color enhancement and their use in assays |
| US5686315A (en) | 1991-06-14 | 1997-11-11 | Quidel Corporation | Assay device for one step detection of analyte |
| JPH07503543A (ja) | 1992-02-04 | 1995-04-13 | クイデル コーポレイション | 乾燥試薬を用いる細菌抗原の簡易化抽出法 |
| US5541069A (en) | 1992-02-28 | 1996-07-30 | Quidel Corporation | Assay having improved dose response curve |
| ES2151902T3 (es) | 1992-03-10 | 2001-01-16 | Quidel Corp | Medio de separacion de globulos rojos para dosificarlos mediante union especifica. |
| DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| US5415994A (en) | 1993-08-02 | 1995-05-16 | Quidel Corporation | Lateral flow medical diagnostic assay device with sample extraction means |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5434057A (en) | 1994-02-02 | 1995-07-18 | Quidel Corporation | Sperm motility assay and devices |
| US5521102A (en) | 1994-08-08 | 1996-05-28 | Quidel Corporation | Controlled sensitivity immunochromatographic assay |
| US5845255A (en) | 1994-10-28 | 1998-12-01 | Advanced Health Med-E-Systems Corporation | Prescription management system |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US5712172A (en) | 1995-05-18 | 1998-01-27 | Wyntek Diagnostics, Inc. | One step immunochromatographic device and method of use |
| US5804452A (en) | 1995-04-27 | 1998-09-08 | Quidel Corporation | One step urine creatinine assays |
| US5786220A (en) | 1995-04-28 | 1998-07-28 | Quidel Corporation | Assays and devices for distinguishing between normal and abnormal pregnancy |
| US20010051350A1 (en) | 1995-05-02 | 2001-12-13 | Albert Nazareth | Diagnostic detection device and method |
| US5773234A (en) | 1995-08-07 | 1998-06-30 | Quidel Corporation | Method and device for chlamydia detection |
| DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| US6305377B1 (en) | 1996-12-12 | 2001-10-23 | Michael T. Portwood | System and method for improving compliance of a medical regimen |
| US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
| US6306642B1 (en) | 1997-11-24 | 2001-10-23 | Quidel Corporation | Enzyme substrate delivery and product registration in one step enzyme immunoassays |
| US6623981B2 (en) | 1998-01-27 | 2003-09-23 | Bristol-Myers Squibb Company | Detection of patients at risk for developing integrin antagonist/agonist mediated disease states |
| US6014631A (en) | 1998-04-02 | 2000-01-11 | Merck-Medco Managed Care, Llc | Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry |
| US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US7171371B2 (en) | 1999-09-03 | 2007-01-30 | Smg Trust | Method and system for providing pre and post operative support and care |
| EP1232392B2 (de) | 1999-10-12 | 2014-04-02 | Oxoid (Ely) Limited | Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl |
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| DE60043308D1 (de) | 1999-12-16 | 2009-12-24 | Biogen Idec Inc | Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin |
| AU2001233034A1 (en) | 2000-01-27 | 2001-08-07 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| AU4465001A (en) | 2000-03-30 | 2001-10-15 | Nippon Kayaku Kabushiki Kaisha | Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor |
| US6620626B1 (en) | 2000-08-09 | 2003-09-16 | Mission Research Corp. | Antigen detection device and method |
| MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
| JP2004511807A (ja) | 2000-10-17 | 2004-04-15 | ベッスト−テスト アンパーツゼルスカブ | 体液サンプル中のｒｓウイルスに関連した生物学的細胞の直接的検出のためのアッセイ |
| US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| US6485460B2 (en) | 2001-01-12 | 2002-11-26 | Bracco Diagnostics, Inc. | Tamper evident syringe barrel |
| AU2002331408B2 (en) | 2001-08-20 | 2008-05-08 | Proteome Systems Ltd | Diagnostic testing process and apparatus |
| WO2003016902A1 (en) | 2001-08-20 | 2003-02-27 | Proteome Systems Intellectual Property Pty Ltd | Diagnostic testing process and apparatus |
| US6605602B1 (en) | 2001-09-28 | 2003-08-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of treating BK virus nephropathy |
| US7754433B2 (en) * | 2001-12-03 | 2010-07-13 | Amgen Fremont Inc. | Identification of high affinity molecules by limited dilution screening |
| PL215263B1 (pl) | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| WO2004001539A2 (en) | 2002-06-21 | 2003-12-31 | Mckesson Information Solutions Llc | Closed loop medication use system and method |
| US20070275481A1 (en) | 2003-11-24 | 2007-11-29 | Biogen Idec Ma Inc. | Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis |
| JP4672263B2 (ja) | 2004-01-27 | 2011-04-20 | デンカ生研株式会社 | 簡便な検出法、検出装置及び検出キットとその製法 |
| US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| US20050283385A1 (en) | 2004-06-21 | 2005-12-22 | The Permanente Medical Group, Inc. | Individualized healthcare management system |
| AR050425A1 (es) | 2004-07-08 | 2006-10-25 | Elan Pharm Inc | Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| NZ581497A (en) | 2004-12-03 | 2012-07-27 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody |
| WO2006112951A2 (en) | 2005-03-03 | 2006-10-26 | Seedlings Life Science Ventures, Llc | Method of risk management for patients undergoing natalizumab treatment |
| DK2645106T4 (da) | 2005-04-04 | 2024-12-02 | Biogen Ma Inc | Fremgangsmåder til evaluering af et immunrespons på et terapeutisk middel |
| EP1915613A4 (en) * | 2005-07-08 | 2008-11-05 | Philadelphia Health & Educatio | METHOD FOR MONITORING THE NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR THE TREATMENT OF DISEASES COMPRISING A COMPOSITION COMPONENT RELATED TO PHOSPHOLIPASE A2 |
| CA2624450C (en) | 2005-09-29 | 2014-02-04 | Elan Pharmaceuticals, Inc. | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| MY151045A (en) | 2006-02-27 | 2014-03-31 | Elan Pharm Inc | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| US8410115B2 (en) | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| WO2007100770A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| RS20080391A (sr) | 2006-03-03 | 2009-07-15 | Elan Pharmaceuticals Inc., | Postupci lečenja zapaljenskih i autoimunih bolesti natalizumabom |
| US20110184747A1 (en) * | 2006-08-09 | 2011-07-28 | Carmen Bozic | Method for distribution of a drug |
| TWI415845B (zh) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| US20080233150A1 (en) | 2006-11-16 | 2008-09-25 | Gale Smith | Respiratory syncytial virus-virus like particle (vlps) |
| EP1933140B1 (en) | 2006-12-11 | 2011-08-17 | AraGen Biotechnology Co. Ltd. | Antibody detection method involving an oligonucleotide enhanced collodial gold signal |
| TW200846363A (en) * | 2007-03-22 | 2008-12-01 | Urrma R & B | Novel human anti-R7V antibodies and uses thereof |
| FR2919804B1 (fr) * | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| GB2483810B (en) * | 2008-11-07 | 2012-09-05 | Sequenta Inc | Methods for correlating clonotypes with diseases in a population |
| ES2842425T3 (es) | 2009-02-05 | 2021-07-14 | Biogen Ma Inc | Métodos para la detección del poliomavirus JC |
| US9354233B2 (en) | 2009-02-20 | 2016-05-31 | The Regents Of The University Of California | A+ biomarker assays |
| RS63744B1 (sr) | 2010-01-11 | 2022-12-30 | Biogen Ma Inc | Test za antitela protiv jc virusa |
| ES2729945T3 (es) | 2011-05-31 | 2019-11-07 | Biogen Ma Inc | Procedimiento para valorar el riesgo de LMP |
| HK1216546A1 (zh) * | 2013-05-28 | 2016-11-18 | Biogen Ma Inc. | 评估pml风险的方法 |
-
2012
- 2012-05-31 ES ES12792375T patent/ES2729945T3/es active Active
- 2012-05-31 HR HRP20230186TT patent/HRP20230186T1/hr unknown
- 2012-05-31 HU HUE19169482A patent/HUE061244T2/hu unknown
- 2012-05-31 CA CA2836490A patent/CA2836490A1/en active Pending
- 2012-05-31 AU AU2012262122A patent/AU2012262122B2/en active Active
- 2012-05-31 SM SM20190336T patent/SMT201900336T1/it unknown
- 2012-05-31 PL PL12792375T patent/PL2715352T3/pl unknown
- 2012-05-31 KR KR1020217026042A patent/KR102473834B1/ko active Active
- 2012-05-31 PT PT12792375T patent/PT2715352T/pt unknown
- 2012-05-31 LT LTEP12792375.3T patent/LT2715352T/lt unknown
- 2012-05-31 CN CN201280026045.5A patent/CN103635803A/zh active Pending
- 2012-05-31 KR KR1020197031074A patent/KR102292563B1/ko active Active
- 2012-05-31 RS RS20190690A patent/RS58967B1/sr unknown
- 2012-05-31 EP EP12792375.3A patent/EP2715352B1/en not_active Revoked
- 2012-05-31 LT LTEP19169482.7T patent/LT3575792T/lt unknown
- 2012-05-31 EP EP19169482.7A patent/EP3575792B1/en active Active
- 2012-05-31 ES ES19169482T patent/ES2939482T3/es active Active
- 2012-05-31 SI SI201232024T patent/SI3575792T1/sl unknown
- 2012-05-31 KR KR1020137031996A patent/KR102039751B1/ko active Active
- 2012-05-31 HR HRP20190860TT patent/HRP20190860T1/hr unknown
- 2012-05-31 DK DK12792375.3T patent/DK2715352T3/da active
- 2012-05-31 SI SI201231596T patent/SI2715352T1/sl unknown
- 2012-05-31 EP EP22209669.5A patent/EP4187248A1/en active Pending
- 2012-05-31 HU HUE12792375A patent/HUE043339T2/hu unknown
- 2012-05-31 PL PL19169482.7T patent/PL3575792T3/pl unknown
- 2012-05-31 FI FIEP19169482.7T patent/FI3575792T3/fi active
- 2012-05-31 RS RS20230142A patent/RS63989B1/sr unknown
- 2012-05-31 SM SM20230060T patent/SMT202300060T1/it unknown
- 2012-05-31 JP JP2014513712A patent/JP6243838B2/ja active Active
- 2012-05-31 WO PCT/US2012/040283 patent/WO2012166971A2/en not_active Ceased
- 2012-05-31 PT PT191694827T patent/PT3575792T/pt unknown
- 2012-05-31 DK DK19169482.7T patent/DK3575792T3/da active
-
2017
- 2017-07-26 JP JP2017144730A patent/JP6663396B2/ja active Active
-
2018
- 2018-12-05 US US16/211,154 patent/US12105090B2/en active Active
-
2019
- 2019-06-03 CY CY20191100584T patent/CY1121981T1/el unknown
-
2020
- 2020-02-14 JP JP2020023062A patent/JP7128221B2/ja active Active
-
2021
- 2021-08-03 US US17/393,335 patent/US12066442B2/en active Active
- 2021-10-13 JP JP2021168084A patent/JP7353338B2/ja active Active
-
2023
- 2023-09-19 JP JP2023151467A patent/JP2023169307A/ja active Pending
-
2024
- 2024-08-19 US US18/809,113 patent/US20250164486A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518377A5 (enExample) | ||
| HRP20250210T1 (hr) | Analiza za antitijela jc virusa | |
| ES2729945T3 (es) | Procedimiento para valorar el riesgo de LMP | |
| JP2019535015A5 (enExample) | ||
| JP2019530875A5 (enExample) | ||
| JP2020517919A5 (enExample) | ||
| CN105765386B (zh) | 用于检测中和抗体的竞争性配体结合测定法 | |
| Ankerhold et al. | Circulating multimeric immune complexes contribute to immunopathology in COVID-19 | |
| EP2952896B1 (en) | Method for reducing false negatives in immunoassay for assaying biomembrane-derived specimen | |
| JP2013516633A5 (enExample) | ||
| WO2015121784A1 (en) | Method for detection of anti-rituximab antibodies | |
| JP2020537128A5 (enExample) | ||
| Mita et al. | Affinity of IgE antibody to antigen influences allergen‐induced histamine release | |
| Pohanka et al. | Diagnosis of tularemia using piezoelectric biosensor technology | |
| Liu et al. | Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia | |
| CN104126124A (zh) | 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物 | |
| Kaplonek et al. | Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles | |
| Amjadi et al. | Novel and unique rheumatoid factors cross-react with viral epitopes in COVID-19 | |
| Perkmann et al. | Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222 | |
| JPWO2018181263A1 (ja) | 体液による抗原抗体反応阻害を防止する物質 | |
| EP2980586B1 (en) | Insulin assay method | |
| Plavina et al. | Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma | |
| JP2013511728A5 (enExample) | ||
| Kaysheva et al. | Mass spectrometric detection of the amino acid sequence polymorphism of the hepatitis C virus antigen | |
| Tsitsilonis et al. | Serological detection of hepatitis B viral infection by a panel of solid-phase enzyme-linked immunosorbent assays (ELISA) |